Leyan Xu works as a Faculty Member in the Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Md, USA. He received his M.D. degree from Norman Bethune University of Medical Sciences (Now Jilin University), Changchun, China, in 1994 and his Ph.D. degree (major in medical image and nuclear medicine) in Peking Union Medical College Hospital (PUMCH) in Peking Union Medical College, Beijing, China, in 2000. He started research in the biomedicine field in 1994 as a graduate student. Dr. Xu has conducted research on various projects in academia in China (1994–2001), University of Maryland (2001–2003), and Johns Hopkins University (JHU) in USA (2003–present). His expertise is in neuroscience including neurodegenerative diseases, stroke, traumatic brain injury, stroke, and schizophrenia. His contributions and outstanding work are highly recognized and adopted by the independent researchers and experts in his field. Dr. Xu has made progress in stem cell therapy on motor neuron diseases (ALS). His research achievement became the principal foundation of motor neuron disease clinical human trials for ALS approved by FDA. In addition, Dr. Xu managed preclinical trial on ALS therapy with umbilical cord blood hematopoietic stem cells sponsored by Johnson & Johnson. Based on this progress, he was invited to be Scientific Advisory Board Member on Cell-Based Therapy in ALS, Johnson & Johnson, 2011. Dr. Xu has received an American Federation for Aging Research (AFAR) Travel Scholarship Award and an American Society for Neural Therapy and Repair (ASNTR) Travel Award.
Biography Updated on 5 April 2013